Pharmacokinetic characterization of a natural product-inspired novel MEK1 inhibitor E6201 in preclinical species

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 1, 2012, Pages 229-237

  Kumar, Vipul ^a   Schuck, Edgar L ^b   Pelletier, Robert D ^b   Farah, Nadia ^b   Condon, Krista B ^b   Ye, Meng ^b   Rowbottom, Christopher ^b   King, Belinda M ^b   Zhang, Zhi Yi ^c   Saxton, Philip L ^b   Wong, Y Nancy ^b  

^a CUBIST PHARMACEUTICALS INC   (United States)

^b EISAI INC   (United States)

^c BIOGEN   (United States)

Author keywords

CYP induction; CYP inhibition; E6201; MEK1 inhibitor; Pharmacokinetics; Protein binding

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIPSORIASIS AGENT; CYTOCHROME; CYTOCHROME P450 1A; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A; DRUG METABOLITE; E 6201; ER 813010; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; NATURAL PRODUCT; UNCLASSIFIED DRUG;

ALLOMETRY; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISTRIBUTION VOLUME; DOG; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG STABILITY; DRUG STRUCTURE; ENZYME INHIBITION; ENZYME METABOLISM; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; MALE; MICROSOME; MOUSE; NONHUMAN; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; PROTEIN INDUCTION; RAT; SINGLE DRUG DOSE;

ANIMALS; CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DOGS; DRUG EVALUATION, PRECLINICAL; HALF-LIFE; HUMANS; LACTONES; MALE; MAP KINASE KINASE 1; MICE; MICE, INBRED BALB C; MICROSOMES, LIVER; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION;

EID: 84856734730     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1687-8     Document Type: Article

References (19)

1. TD Bjornsson JT Callaghan HJ Einolf V Fischer L Gan S Grimm J Kao SP King G Miwa L Ni G Kumar J McLeod RS Obach S Roberts A Roe A Shah F Snikeris JT Sullivan D Tweedie JM Vega J Walsh SA Wrighton 2003 The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective Drug Metab Dispos 31 7 815 832 12814957 10.1124/dmd.31.7.815 1:CAS:528:DC%2BD3sXltFalu70%3D (Pubitemid 36759050)
2. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA (2002) Mutations of the BRAF gene in human cancer. Nature. ;417(6892):949-954 (Pubitemid 34716871)
3. GA Ellestad FM Lovell NA Perkinson RT Hargreaves WJ McGahren 1978 New zearalenone related macrolides and isocoumarins from an unidentified fungus J Org Chem 43 2339 2343 10.1021/jo00406a007 1:CAS:528:DyaE1cXktF2rsr0%3D (Pubitemid 8353693)
4. Gabrielsson J, Weiner D (2000) Pharmacokinetic and pharmacodynamic data analysis. Swedish pharmaceutical press, Stockholm, Sweden
5. M Goto J Chow K Muramoto K Chiba S Yamamoto M Fujita H Obaishi K Tai Y Mizui I Tanaka D Young H Yang YJ Wang H Shirota F Gusovsky 2009 E6201 [(3S, 4R, 5Z, 8S, 9S, 11E)-14-(ethylamino)-8, 9, 16-trihydroxy-3, 4-dimethyl-3, 4, 9, 19-tetrahydro-1H-2-benzoxacyclotetradecine-1, 7(8H)-dione], a novel kinase inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK)-1 and MEK kinase-1: In vitro characterization of its anti-inflammatory and antihyperproliferative activities J Pharmacol Exp Ther 331 2 485 495 19684251 10.1124/jpet.109.156554 1:CAS:528:DC%2BD1MXhtlKnu7zO
6. CR Gregg 1999 Drug interactions and anti-infective therapies Am J Med 106 227 237 10230754 10.1016/S0002-9343(98)00408-2 1:STN:280:DyaK1M3ksFOrtw%3D%3D (Pubitemid 29115965)
7. Guidance for industry draft guidance (2006) Drug interaction studies-study design, data analysis, and implications for dosing and labeling. Available via DIALOG. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm072101.pdf. Accessed March 24, 2010
8. JH Lin AY Lu 1997 Role of pharmacokinetics and metabolism in drug discovery and development Pharmacol Rev 49 4 403 449 9443165 1:CAS:528:DyaK1cXjslSrtQ%3D%3D (Pubitemid 28030947)
9. JH Lin AY Lu 1998 Inhibition and induction of cytochrome P450 and the clinical implications Clin Pharmacokinet 35 361 390 9839089 10.2165/00003088- 199835050-00003 1:CAS:528:DyaK1cXnvVeqtLo%3D (Pubitemid 28520008)
10. Mahmood I (2005) Interspecies pharmacokinetic scaling allometric principles and applications. Pine house publishers, Rockville, Maryland
11. Nomoto K, Wang J, Wu J, Agoulnik S, Kuznetsov G, Towle MJ, Schnaderbeck M, Gusovsky F, Shirota H, Littlefield BA (2009) In vitro antiproliferative activity of natural product-based MEK1 inhibitor E6201 against V600E BRAF-mutated cancer cell lines (abstract 3690). In: Annual meeting of the American Association for Cancer Research, Denver, CO. (18-22 April 2009)
12. JL Raucy L Mueller K Duan SW Allen S Strom JM Lasker 2002 Expression and induction of CYP2C P450 enzymes in primary cultures of human hepatocytes J Pharmacol Exp Ther 302 475 482 12130704 10.1124/jpet.102.033837 1:CAS:528:DC%2BD38Xls1Ogsb8%3D (Pubitemid 34787209)
13. D Runge C Kohler VE Kostrubsky D Jager T Lehmann DM Runge U May DB Stolz SC Strom WE Fleig GK Michalopoulos 2000 Induction of cytochrome P450 (CYP)1A1, CYP1A2, and CYP3A4 but not of CYP2C9, CYP2C19, multi-drug resistance (MDR-1) and multi-drug resistance associated protein (MRP-1) by prototypical inducers in human hepatocytes Biochem Biophys Res Commun 273 333 341 10873607 10.1006/bbrc.2000.2902 1:CAS:528:DC%2BD3cXkt1Knu74%3D (Pubitemid 30426907)
14. BoivinR ShenY N Yoneda H Du S Schiller T Matsushima M Goto H Shirota F Gusovsky C Lemelin Y Jiang Z Zhang R Pelletier M Ikemori-Kawada Y Kawakami A Inoue M Schnaderbeck Y Wang 2010 Discovery of anti-inflammatory clinical candidate E6201, inspired from resorcylic lactone LL-Z1640-2, III Bioorganic Medicinal chemistry letter 20 3155 3157 10.1016/j.bmcl.2010.03.087
15. EM Wallace JP Lyssikatos T Yeh JD Winkler K Koch 2005 Progress towards therapeutic small molecule MEK inhibitors for use in cancer therapy Curr Top Med Chem 5 2 215 229 15853648 10.2174/1568026053507723 1:CAS:528: DC%2BD2MXjtFyksbs%3D (Pubitemid 40520463)
16. JY Wang KM Wilcoxen K Nomoto S Wu 2007 Recent advances of MEK inhibitors and their clinical progress Curr Top Med Chem 7 14 1364 1378 17692026 10.2174/156802607781696837 1:CAS:528:DC%2BD2sXht1SmtbrL (Pubitemid 47471235)
17. JP Whitlock Jr 1999 Induction of cytochrome P4501A1 Annu Rev Pharmacol Toxicol 39 103 125 10331078 10.1146/annurev.pharmtox.39.1.103 1:CAS:528:DyaK1MXjtVejt70%3D (Pubitemid 29222553)
18. Wu J, Nomoto K, Wang J, Kuznetsov G, Agoulnik S, Shuck E, Wong N, Towle MJ, Schnaderbeck M, Wu S, Littlefield BA (2009) In vivo anticancer activity of E6201, a novel MEK1 inhibitor, against BRAF-mutated human cancer xenografts (abstract 3687). In: Annual meeting of the American Association for Cancer Research, Denver, CO. (18-22 April 2009)
19. L Xu AP Li DL Kaminski MF Ruh 2000 2, 3, 7, 8 Tetrachlorodibenzo-p- dioxin induction of cytochrome P4501A in cultured rat and human hepatocytes Chem Biol Interact 124 173 189 10728777 10.1016/S0009-2797(99)00149-0 1:CAS:528:DC%2BD3cXpsFWrtA%3D%3D (Pubitemid 30072751)